Abstract

Introduction: Dysmenorrhea attacks may be accompanied by extragenital symptoms such as nausea, vomiting, diarrhea, headache and leg pain and by emotional symptoms such as tension and irritability. Therefore, we think that dysmenorrheic symptoms may be more severe in patients with dyspeptic symptoms. The purpose of this study was to determine whether pain scores would differ between dysmenorrheic patients with or without dyspeptic symptoms.

Methods: Patients presenting to the emergency department with dysmenorrhea attacks and volunteering to participate were included in this case-control study. Subjects with dyspeptic symptoms were enrolled as the case group and those without dyspeptic symptoms were enrolled as the control group. Participants were administered the Faces Pain Scale and a questionnaire involving demographic characteristics.

Results: Pain scores on arrival were higher in the case group than in the control group (4.20 ± 0.71, 3.70 ± 0.74, n=30, p=0.011). A significant difference was observed between pain scores on arrival and at discharge in both the control and case groups. A decrease in pain scores was determined in all the subjects in the case group, while no change was observed in three volunteers in the control group.

Conclusions: We conclude that pain is significantly more severe in dysmenorrheic patients with dyspeptic symptoms.

Introduction

Dysmenorrhea attacks may be accompanied by extragenital symptoms such as nausea, vomiting, diarrhea, headache and leg pain and by emotional symptoms such as tension and irritability [1]. Ischemia and myometrial contraction caused by prostaglandins of uterine origin are implicated in the pathology of dysmenorrhea [2]. Prostaglandin-suppressing non-steroid anti-inflammatory drugs are therefore the first choice in the pharmacological treatment of dysmenorrhea [3]. In addition to supporting treatments such as a fat-poor diet, vitamin B1, vitamin B6, vitamin E and magnesium, acupuncture and exercise have also been reported to reduce the symptoms of dysmenorrhea as alternatives to pharmacological treatment [4].

Increased activation of vagal afferents following either gastrointestinal dysrythmia or dysmotility or following abnormal distension of the stomach, intestine or biliary tract also evokes nausea [5]. In addition, both vagus nerve and peripheral vagal nerve terminals play an active role in the development of symptoms of the gastrointestinal tract such as nausea, vomiting and diarrhea [6]. Some studies indicate that women experience more abdominal symptoms at the beginning of the follicular phase [7,8]. During menstruation, one-third of asymptomatic women may experience gastrointestinal symptoms and an increase in symptoms in almost 50% of women with irritable bowel syndrome [9-11].

Some studies have suggested that histamine released by histaminergic neurons in the fundus region of the rat stomach and in the pig ileum are involved in gastrointestinal symptoms [12,13]. Gastrin stimulates acid secretion by releasing histamine from enterochromaffin-like cells [14]. Moreover, vagal-induced acid secretion is also dependent on a histaminergic pathway but not on enterochromaffin-like cell histamine [15-18]. Recent studies have shown that histamine plays a role in small bowel and colon disorders such as irritable bowel syndrome and colitis [19,20].

There are studies suggesting that the uterus is stimulated by the innervation of the vagus nerve [21,22]. Moreover, it has been shown that the induction of pseudopregnancy in response to cervical stimulation was interrupted by abdominal vagotomy [23]. Additionally, histamine has been shown to cause contraction in the mouse uterus [24-26]. Therefore, we think that dysmenorrheic symptoms may be more severe in patients with dyspeptic symptoms. We also suggest that pain scores in dysmenorrheic patients with dyspeptic syndromes are higher than in patients without dyspeptic syndromes. The purpose of this study was to...
determine whether pain scores would differ between dysmenorrheic patients with or without dyspeptic symptoms.

Materials And Methods
This research was performed as a case-control study. This study was approved by the ethical committee. Thirty dysmenorrheic patients with dyspeptic symptoms presenting to the Nevşehir Public Hospital Emergency Department were enrolled as the case group, and 30 dysmenorrheic patients without dyspeptic symptoms were enrolled as the control group. Participants were administered a Face Pain Scale containing five different facial expressions with values between one and five at the time of the first presentation. The Face Pain Scale was repeated at the end of treatment. Participants were also administered a questionnaire involving demographic characteristics.

Patients of reproductive age, on the first day of the dysmenorrheic attack, with no history of any drug use, not using pregnancy-preventing drugs, not in the breastfeeding period and with no amenorrhea were included in the study.

All statistical analyses were performed with IBM SPSS Statistics (V25; IBM Corp., Armonk, NY). A P-value less than 0.05 was considered statistically significant. Demographic properties were compared with the chi-square test. Numeric data were expressed as mean values and were analyzed using the independent-samples t-test in independent groups and the paired-samples t-test in dependent groups.

Results
No difference was observed between the case and control groups' demographic properties, in terms of age, body mass index (BMI), education level, marital status, smoking and alcohol use, chronic disease or medication use. A statistically significant difference was determined in terms of employment. Three patients (5%) of the case group regularly worked while 27 patients (45%) irregularly worked, while in the control group 14 patients (26.7%) regularly worked while 16 patients (23.3%) did not work (p=0.003; Table 1).
| Characteristics of participants | Case (n=30) | Control (n=30) |
|--------------------------------|------------|---------------|
| Age (mean ± SD)                | 20.64±6.35 | 20.79 ± 2.87  |
| BMI (mean ± SD)                | 21.87±2.95 | 21.67 ± 3.20  |
| Education n (%)                |            |               |
| Prime level                    | 7 (11.7)   | 3 (5)         |
| High level                     | 23 (38.3)  | 27 (45)       |
| Employment n (%)<sup>a</sup>   |            |               |
| Regularly                      | 3 (5)      | 14 (23.3)     |
| Irregularly                    | 27 (45)    | 19 (26.7)     |
| Marital status n (%)           |            |               |
| Marriage                       | 5 (8.3)    | 6 (10)        |
| Single                         | 25 (41.7)  | 24 (40)       |
| Smoking n (%)                  |            |               |
| Not use                        | 23 (38.3)  | 20 (33.3)     |
| Use                            | 7 (11.7)   | 10 (16.7)     |
| Alcohol n (%)                  |            |               |
| Not use                        | 30 (50)    | 27 (45)       |
| Use                            | 0 (0)      | 3 (5)         |
| Chronic disease n (%)          |            |               |
| No                             | 27 (45)    | 28 (46.7)     |
| Yes                            | 3 (5)      | 2 (3.3)       |
| Medication n (%)               |            |               |
| Not use                        | 29 (48.3)  | 28 (46.7)     |
| Use                            | 1 (1.7)    | 2 (3.3)       |

**TABLE 1: Comparison of demographic properties between case and control groups.**

The statistically significant difference was accepted as p<0.05.

<sup>a</sup>Significant; p=0.003.

A statistically significant difference was also determined between the case and control groups in terms of mean pain scores. Pain scores at the time of presentation were significantly higher in the case group than in the control group (4.20 ± 0.71, 3.70 ± 0.74, n=30, p=0.011). Statistically significant differences between pain scores at the time of presentation and time of discharge were observed in both the case and control groups (Table 2).
### TABLE 2: Comparison of pain scores at the time of presentation and discharge between two paired groups.

*SD: standard deviation.

| Group   | Time of presentation | n   | Mean ± SD | t-Value | p-Value |
|---------|----------------------|-----|-----------|---------|---------|
| Case    |                      | 30  | 4.20 ± 0.71 | 19.33   | 0.001   |
|         | Time of discharge    | 30  | 1.86 ± 0.73 |         |         |
| Control |                      | 30  | 3.70 ± 0.74 | 9.64    | 0.001   |
|         | Time of discharge    | 30  | 2.06 ± 0.82 |         |         |

A decrease in pain scores after discharge was determined in all the subjects in the case group, but no change in pain scores was observed in three volunteers in the control group. The decrease in pain scores between the time of presentation and time of discharge was greater in the case group than in the control group (2.33 ± 0.66, 1.63 ± 0.92, n=30, p=0.001; Figure 1).

### FIGURE 1: Comparison of pain scores at time of presentation and discharge between two independent groups.

#### Discussion

We think that our study is unique since our scan of the literature revealed no previous such research. The absence of any difference between the control and case groups in terms of demographic characteristics other than employment shows that the study was well randomized and powerful.

Pain scores at the time of presentation to the emergency department in our study were significantly higher in the case group than in the control group. The reason for these pain scores being higher may be associated with dyspeptic symptoms. Although the major parasympathetic impulse system of the uterus derives from the sacral region of the medulla spinalis, the uterus also receives parasympathetic fibers via the vagus nerve [21,22]. Gastrointestinal symptoms being reported to vary during the phases of the menstrual cycle supports those studies suggesting that the uterus is under the effect of the vagus nerve [7,8,21-23]. Increased parasympathetic innervation gives rise to dysrhythmia, dysmotility, distension, nausea, vomiting and diarrhea in the gastrointestinal system and causes contractions in the uterus [5,6,21-23]. Symptoms seen in both the gastrointestinal system and the uterus in dysmenorrhea attack accompanied by dyspeptic symptoms resemble the effects of increased vagus nerve-mediated parasympathetic innervation. However,
gastrointestinal symptoms being seen in only one-third of asymptomatic women during menstruation shows that a different mechanism similar to the parasympathetic effects of the vagus nerve is also involved [9-11]. Histamine possesses effects similar to increased parasympathetic innervation in both the uterus and the gastrointestinal system. Histamine release causes contraction in the uterus [24-26]. Gastrin has been shown to increase gastric acid secretion by causing histamine secretion from enterochromaffin-like cells while vagus nerve innervation causes an increase in gastric acid secretion by causing histamine secretion by a different histaminergic pathway [14-18]. In addition, the presence of histaminergic neurons has been demonstrated in both the fundus of the rat stomach and in the pig small bowel [12,13]. In the light of all this information, we think that gastrointestinal symptoms seen in some patients with dysmenorrhea derive from the release of histamine from vagus nerve-mediated histaminergic pathways or neurons. Moreover, studies both reporting that worsened symptoms of irritable bowel syndrome at the time of menstruation and indicating that histamine is involved in the irritable bowel syndrome support our thesis concerning histamine [9-11,19,20]. In other words, histamine may have played an effective role in dyspeptic symptoms seen during dysmenorrhea attacks.

In addition, the decrease in pain scores between the time of presentation and discharge was more pronounced in the case group. While pain scores decreased in all patients in the case group, no change was determined in three members of the control group. Being better improvement at discharge in the case group despite their pain scores being higher than those of the control group may be attributed to the addition of treatments aimed at the dyspeptic symptoms. The presence of a more pronounced improvement at the time of discharge in the case group compared to the control group may therefore derive from the H2 receptor antagonists added to treatment. We suggest that the increase in pain score at the time of arrival in the case group may be histamine-related. This finding from our study also supports our thesis concerning the effects of histamine in patients with dysmenorrhea. However, the fact that we do not know whether there exists in the uterus a pathway similar to the vagus nerve-mediated histaminergic pathways shown to be present in the gastrointestinal system weakens the validity of our thesis. For that reason, further research into this subject including animal experiments is needed regarding the parasympathetic innervation of the uterus.

Conclusions

Consequently, severity of pain is worse in dysmenorrheic attacks accompanied by dyspeptic symptoms. We therefore think that the addition of an H2 receptor blocker drug to treatment during menstruation will contribute to a decrease in the symptoms of dysmenorrhea, a cause of considerable discomfort to women. We also think that wider-ranging studies are now needed on the subject.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Sakarya University Medical Faculty Non-Invasive Ethics Committee issued approval 71522475.050.01/04/14. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. De Sanctis V, Soliman A, Bernasconi S, et al.: Primary dysmenorrhea in adolescents: prevalence, impact and recent knowledge. Pediatr Endocrinol Rev. 2015, 15:S12-20.
2. Proctor M, Farquhar C: Diagnosis and management of dysmenorrhea. BMJ. 2006, 332:S134-8. 10.1136/bmj.332.7550.1134
3. Feng X, Wang X: Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis. Mol Pain. 2018, 14:174480691870520. 10.1177/174480691870520
4. French L: Dysmenorrhea. Am Fam Physician. 2005, 71:S135-91.
5. Grundy D: Neuroanatomy of visceral nociception: vagal and splanchnic afferent. Gut. 2002, 51:S12-5. 10.1136/gut.51.suppl_1.S12
6. Babic T, Browning KN: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur J Pharmacol. 2014, 722:S38-47. 10.1016/j.ejphar.2013.08.047
7. Gill BC, Murphy P, Hooper HR, Bowes KL, Kingma YI: Effect of the menstrual cycle on gastric emptying. Digestion. 1987, 56:S168-74. 10.1159/000199414
8. Björnsson B, Orvar KB, Theodórs A, Kjeld M: The relationship of gastrointestinal symptoms and menstrual phase in young healthy women. Laeknabladid. 2006, 92:677-82.
9. Altman G, Cain KC, Motzer S, Jarrett M, Burr R, Heitkemper M: Increased symptoms in female IBS patients with dysmenorrhea and PMS. Gastroenterol Nurs. 2006, 29:S4-11. 10.1097/00001610-200601000-00002
10. Kane SV, Sahle K, Hanauer SB: The menstrual cycle and its effect on inflammatory bowel disease and
irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998, 93:1867-72. 10.1111/j.1572-0241.1998.0011.x

11. Moore J, Barlow D, Jewell D, Kenneely S: Do gastrointestinal symptoms vary with the menstrual cycle?. Br J Obstet Gynaecol. 1998, 105:1522-5. 10.1111/j.1471-0528.1998.tb0014.x

12. Coruzzi G, Morini G, Adami M, Grandi D: Role of histamine H3 receptors in the regulation of gastric functions. J Physiol Pharmacol. 2001, 52:539-53.

13. Izzo AA, Costa M, Mascolo N, Capasso F: The role of histamine H1, H2 and H3 receptors on enteric ascending synaptic transmission in the guinea pig ileum. J Pharmacol Exp Ther. 1998, 287:952-7.

14. Andersson K, Cabero JL, Mattsson H, Håkanson R: Gastric secretion after depletion of enterochromaffin-like cell histamine. A study with alpha-fluoromethylhistidine in rats. Scand J Gastroenterol. 1996, 31:24-30. 10.3109/00365529609031622

15. Christie AE, Stein W, Quinlan JE, Beenakker MP, Marder E, Nusbaum MP: Actions of a histaminergic/peptidergic projection neuron on rhythmic motor patterns in the stomatogastric nervous system of the crab Cancer borealis. J Comp Neurol. 2004, 469:155-69. 10.1002/cne.11003

16. Pulver SR, Thirumalai V, Richards KS, Marder E: Dopamine and histamine in the developing stomatogastric system of the lobster Homarus americanus. J Comp Neurol. 2003, 462:408-14. 10.1002/cne.10767

17. Bruce LA, Behnus FI, Fawcett CP: Histaminergic involvement in thyrotropin-releasing hormone stimulation of antral tissue in the rat. Gastroenterology. 1979, 76:908-12.

18. Sandvik AK, Kleveland PM, Waldum HL: Muscarinic M2 stimulation releases histamine in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol. 1988, 23:1049-56. 10.3109/00365528809090168

19. Sullivant A, Mackin A, Pharr T, Cooley J, Wills R, Archer T: Identification of histamine receptors in the canine gastrointestinal tract. Vet Immunol Immunopathol. 2016, 182:29-36. 10.1016/j.vetimm.2016.09.010

20. Wood JD: Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies. Gut. 2006, 55:445-7. 10.1136/gut.2005.079046

21. Collins JJ, Lin CE, Berthoud HR, Papka RE: Vagal afferents from the uterus and cervix provide direct connections to the brainstem. Cell Tissue Res. 1999, 295:43-54. 10.1007/s004410051211

22. Ortega-Villalobos M, García-Bazán M, Solano-Flores LP, Ninomiya-Alarcón JG, Guevara-Guzmán R, Wayner MJ: Vagus nerve afferent and efferent innervation of the rat uterus: an electrophysiological and HRP study. Brain Res Bull. 1990, 25:365-71. 10.1016/0361-9230(90)90221-k

23. Burden HW, Lawrence IE Jr, Louis TM, Hudson CA: Effect of abdominal vagotomy on the estrous cycle of the rat and the induction of pseudopregnancy. Neuroendocrinology. 1981, 35:218-22. 10.1159/000123252

24. Goyal RK, Verma SC: Pharmacological investigations into the effects of histamine and histamine analogs on guinea pig and rat uterus. Agents Actions. 1981, 11:312-7. 10.1007/BF01982464

25. Hill SJ: Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev. 1990, 42:45-83.

26. Martinez-Mir I, Estan L, Morales-Olivas FJ, Rubio E: Studies of the spontaneous motility and the effect of histamine on isolated myometrial strips of the nonpregnant human uterus: the influence of various uterine abnormalities. Am J Obstet Gynecol. 1990, 163:189-95. 10.1016/s0002-9378(11)90697-8